Compare Quest Diagnostics Inc (DGX) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Teradyne, Inc. — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.23B), while Teradyne, Inc. trades at $388.91 (market cap $57.08B). The key difference: Teradyne, Inc. is far larger — about 2.2× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | TER | |
|---|---|---|
Market Cap | $26.23B | $57.08B |
Sector | Health | Technology |
52-Week High | $238.50 | $483.84 |
52-Week Low | $173.49 | $109.30 |
Enterprise Value | $31.99B | $56.83B |
Dividend Yield | 1.45% | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $238.35, down slightly by 0.06% today, but maintains a bullish technical trend with strong earnings momentum, having beaten EPS estimates in the last three quarters. Revenue grew to $11.04 billion in 2025, with net income reaching $992 million, and the company raised its 2026 outlook amid surging testing demand. Analyst consensus is a Buy with a $249.50 price target, though valuation multiples like a P/E of 25.3 suggest premium pricing.
The outlook for DGX is positive due to robust demand for diagnostic services, AI integration, and partnerships driving growth, but risks include margin pressure from lower-margin deals and high debt levels. Investors may find opportunity in sustained earnings beats and dividend payouts, yet should monitor competitive and cost pressures that could affect profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
